Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.05
-1.7%		$6.21
$4.33
▼
$8.00
$2.30B0.372.06 million shs1.27 million shs
CorMedix Inc stock logo
CRMD
CorMedix
$7.32
+0.5%		$7.86
$6.13
▼
$13.02
$567.43M1.4869,869 shs1.02 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$22.38
+1.3%		$26.55
$21.46
▼
$47.65
$1.95B0.691.41 million shs2.25 million shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$47.87
+0.6%		$49.64
$42.62
▼
$71.07
$2.25B0.34655,016 shs558,506 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
+2.31%+5.67%-5.89%+26.78%-3.75%
CorMedix Inc stock logo
CRMD
CorMedix
0.00%-5.45%-13.64%-16.03%-34.36%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
+0.64%-12.10%-21.69%-23.72%-41.34%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
+2.14%+3.58%-8.81%-1.88%-24.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.05
-1.7%		$6.21
$4.33
▼
$8.00
$2.30B0.372.06 million shs1.27 million shs
CorMedix Inc stock logo
CRMD
CorMedix
$7.32
+0.5%		$7.86
$6.13
▼
$13.02
$567.43M1.4869,869 shs1.02 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$22.38
+1.3%		$26.55
$21.46
▼
$47.65
$1.95B0.691.41 million shs2.25 million shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$47.87
+0.6%		$49.64
$42.62
▼
$71.07
$2.25B0.34655,016 shs558,506 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
+2.31%+5.67%-5.89%+26.78%-3.75%
CorMedix Inc stock logo
CRMD
CorMedix
0.00%-5.45%-13.64%-16.03%-34.36%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
+0.64%-12.10%-21.69%-23.72%-41.34%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
+2.14%+3.58%-8.81%-1.88%-24.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
2.14
Hold$8.0032.34% Upside
CorMedix Inc stock logo
CRMD
CorMedix
2.78
Moderate Buy$15.00104.92% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.50
Moderate Buy$48.80118.05% Upside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.40
Hold$67.6741.36% Upside

Current Analyst Ratings Breakdown

Latest CRMD, BHC, PBH, and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSector Perform$9.00
9/30/2026
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/23/2026
CorMedix Inc stock logo
CRMD
CorMedix
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$15.00
9/22/2026
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/21/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/11/2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/20/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/14/2026
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$13.00 ➝ $14.00
8/13/2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/11/2026
CorMedix Inc stock logo
CRMD
CorMedix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/10/2026
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$10.27B0.22$7.28 per share0.83$1.02 per share5.93
CorMedix Inc stock logo
CRMD
CorMedix
$311.71M1.83$2.06 per share3.56$5.14 per share1.42
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$8.17 per shareN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.09B2.08$5.37 per share8.92$39.89 per share1.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$157M-$2.96N/A1.50N/A-10.12%-561.95%6.31%10/28/2026 (Estimated)
CorMedix Inc stock logo
CRMD
CorMedix
$163.05M$2.143.4252.291.3540.49%40.52%20.61%11/11/2026 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$154.65M-$4.24N/AN/AN/AN/A-57.97%-54.15%11/9/2026 (Estimated)
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$190.30M$3.5713.419.401.4615.57%11.39%5.66%11/5/2026 (Estimated)

Latest CRMD, BHC, PBH, and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q2 2027
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.07N/AN/AN/A$329.15 millionN/A
10/28/2026Q3 2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$1.24N/AN/AN/A$2.70 billionN/A
8/13/2026Q2 2026
CorMedix Inc stock logo
CRMD
CorMedix
$0.2380$0.29+$0.0520$0.29$96.04 million$101.93 million
8/12/2026Q2 2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$0.5486-$2.85-$2.3014-$2.85N/AN/A
8/6/2026Q1 2027
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$0.8940$0.98+$0.0860$0.61$253.02 million$265.71 million
7/29/2026Q2 2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.96$1.26+$0.30$0.68$2.59 billion$2.83 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.44
1.08
CorMedix Inc stock logo
CRMD
CorMedix
0.31
2.56
2.36
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
0.18
34.46
34.46
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
1.06
3.23
1.99

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20.67%
CorMedix Inc stock logo
CRMD
CorMedix
3.50%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
18.94%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,300374.38 million297.00 millionOptionable
CorMedix Inc stock logo
CRMD
CorMedix
19177.94 million75.22 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
7688.41 million71.66 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
89047.38 million46.66 millionOptionable

Recent News About These Companies

163,834 Shares in Prestige Consumer Healthcare Inc. $PBH Bought by Congress Asset Management Co.
October 8 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-163834-shares-in-prestige-consumer-healthcare-inc-pbh-bought-by-congress-asset-management-co-2026-10-08/
Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Zacks Research
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-prestige-consumer-healthcare-nyse-pbh-stock-rating-upgraded-by-zacks-research-2026-10-02/
Best Value Stocks to Buy for October 1st
October 1, 2026  |  zacks.comhttps://www.zacks.com/commentary/2998671/best-value-stocks-to-buy-for-october-1st?cid=cs-stocknewsapi-ft-zacks_1_rank_additions|value_additions-2998671
PBH vs. NEOG: Which Stock Is the Better Value Option?
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998307/pbh-vs-neog-which-stock-is-the-better-value-option?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-2998307
More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/more-than-half-of-us-women-have-avoided-talking-about-an-intimate-wellness-concern-because-they-felt-embarrassed-or-uncomfortable-new-summers-eve-survey-finds-302893755.html
Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings?
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/prestige-consumer-healthcare-pbh-fallen-200605339.html
Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 Targets
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/prestige-consumer-healthcare-pbh-could-020809809.html
Critical Contrast: GSK (NYSE:GSK) versus Prestige Consumer Healthcare (NYSE:PBH)
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31057558
Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-prestige-consumer-healthcare-eyes-clear-eyes-recovery-270m-free-cash-flow-2026-09-27/
555,894 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Bank of America Corp DE
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-555894-shares-in-prestige-consumer-healthcare-inc-pbh-purchased-by-bank-of-america-corp-de-2026-09-24/
Prestige Consumer Healthcare stock gains ahead of Sidoti event
September 22, 2026  |  ad-hoc-news.deA
Prestige Consumer Healthcare stock falls as analysts stay cautious
September 20, 2026  |  ad-hoc-news.deA
Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Hold" from Brokerages
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-prestige-consumer-healthcare-inc-nyse-pbh-receives-consensus-recommendation-of-hold-from-brokerages-2026-09-20/
Prestige Consumer Healthcare stock falls after sharp drop toward 52-week low
September 19, 2026  |  ad-hoc-news.deA
PBH or NEOG: Which Is the Better Value Stock Right Now?
September 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2989291/pbh-or-neog-which-is-the-better-value-stock-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-2989291
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945270-prestige-consumer-healthcare-inc-pbh-presents-at-barclays-19th-annual-global-consumer-staples
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358162/0/en/prestige-consumer-healthcare-inc-to-participate-in-barclays-global-consumer-conference.html
Public Employees Retirement System of Ohio Takes $1.55 Million Position in Prestige Consumer Healthcare Inc. $PBH
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-takes-155-million-position-in-prestige-consumer-healthcare-inc-pbh-2026-09-08/
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/football-stress-may-be-following-fans-to-bed-according-to-the-inaugural-dentek-football-stress-test-302865897.html
PBH vs. SYK: Which Stock Is the Better Value Option?
August 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2981979/pbh-vs-syk-which-stock-is-the-better-value-option?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-2981979
Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (OtherSPGDF) and Prestige Consumer Healthcare (PBH)
August 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PBH/pressreleases/3719155/analysts-offer-insights-on-na-companies-springer-nature-ag-co-kgaa-otherspgdf-and-prestige-consumer-healthcare-pbh/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.04 -0.11 (-1.71%)
Closing price 03:59 PM Eastern
Extended Trading
$6.09 +0.04 (+0.73%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

CorMedix stock logo

CorMedix NASDAQ:CRMD

$7.32 +0.04 (+0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$7.30 -0.02 (-0.25%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$22.38 +0.29 (+1.31%)
Closing price 04:00 PM Eastern
Extended Trading
$22.36 -0.02 (-0.07%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$47.87 +0.30 (+0.62%)
Closing price 03:59 PM Eastern
Extended Trading
$47.87 +0.00 (+0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas